

PATENT COOPERATION TREATY

PLS

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

Rec'd PCT/PTO
PCT
9 NOV 2004

14 JAN 2005

To:

Global Intellectual
AstraZeneca
151 85 SÖDERTÄLJE

| | | | |
|-------------------|------|-----|-------------------------------------|
| CODE | DATE | NTD | |
| | | | |
| ANKOM 05 NOV 2004 | | | GIPS |
| DATA | | | Date of mailing (day/month/year) |
| ENTERED | | | 04-11-2004 |

**NOTIFICATION OF TRANSMITTAL OF
INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY**
(Chapter II of the Patent Cooperation Treaty)

(PCT Rule 71.1)

Applicant's or agent's file ref.
100770-1 WO

| | |
|----------------|--|
| FINAL CHECK | |
|----------------|--|

IMPORTANT NOTIFICATION

| | | |
|---|---|---|
| International application No. PCT/SE2003/001216 | International filing date (day/month/year) 15-07-2003 | Priority date (day/month/year) 17-07-2002 |
|---|---|---|

Applicant
AstraZeneca AB
et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the *PCT Applicant's Guide*.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed invention is patentable or not" (see Also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

| | | |
|--|-----------------------------|---|
| Name and mailing address of the IPEA/ Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-687 72 88 | Telex 17978 PATOREG-S | Authorized officer <div style="text-align: right;">Håkan Mattsson</div> Telephone No. 08-782 25 00 |
|--|-----------------------------|---|

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

| | | | | | | | | | |
|--|--|--|--|------|---------|-------|---------------------------|--|--|
| Applicant's or agent's file reference 100770-1 WO | FOR FURTHER ACTION See Form PCT/IPEA/416 | | | | | | | | |
| International application No. PCT/SE2003/001216 | International filing date (day/month/year) 15.07.2003 | Priority date (day/month/year) 17.07.2002 | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">CODE</td> <td style="width: 33%;">DATE</td> <td style="width: 33%;">NTD</td> </tr> <tr> <td></td> <td></td> <td></td> </tr> </table> | CODE | DATE | NTD | | | |
| CODE | DATE | NTD | | | | | | | |
| | | | | | | | | | |
| International Patent Classification (IPC) or national classification and IPC C07D 209/30, A61K 31/405, A61P 11/00 | | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;"></td> <td style="width: 33%;"></td> <td style="width: 33%;"></td> </tr> <tr> <td colspan="3" style="text-align: center;">ANKOM 05 NOV 2004 GIPS</td> </tr> </table> | | | | | ANKOM 05 NOV 2004 GIPS | | |
| | | | | | | | | | |
| ANKOM 05 NOV 2004 GIPS | | | | | | | | | |
| Applicant AstraZeneca AB et al | | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">DATA</td> <td style="width: 33%;">ENTERED</td> <td style="width: 33%;">FINAL</td> </tr> <tr> <td colspan="3" style="text-align: center;">CHECK</td> </tr> </table> | | DATA | ENTERED | FINAL | CHECK | | |
| DATA | ENTERED | FINAL | | | | | | | |
| CHECK | | | | | | | | | |

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 4 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:
 - a. ☐ (sent to the applicant and to the International Bureau) a total of _____ sheets, as follows:
 - ☐ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).
 - ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.
 - b. ☐ (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) _____, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).

4. This report contains indications relating to the following items:

- | | | |
|-------------------------------------|--------------|---|
| <input checked="" type="checkbox"/> | Box No. I | Basis of the report |
| <input type="checkbox"/> | Box No. II | Priority |
| <input checked="" type="checkbox"/> | Box No. III | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability |
| <input type="checkbox"/> | Box No. IV | Lack of unity of invention |
| <input checked="" type="checkbox"/> | Box No. V | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| <input type="checkbox"/> | Box No. VI | Certain documents cited |
| <input type="checkbox"/> | Box No. VII | Certain defects in the international application |
| <input type="checkbox"/> | Box No. VIII | Certain observations on the international application |

| | |
|---|--|
| Date of submission of the demand 30.01.2004 | Date of completion of this report 02.11.2004 |
| Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. +46 8 667 72 88 | Authorized officer Solveig Gustavsson/BS Telephone No. +46 8 782 25 00 |

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/SE2003/001216

Box No. I Basis of the report

1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This report is based on a translation from the original language into the following language _____, which is the language of a translation furnished for the purposes of:

- ☐ international search (under Rules 12.3 and 23.1(b))
☐ publication of the international application (under Rule 12.4)
☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):

☒ the international application as originally filed/furnished

☐ the description:

pages _____ as originally filed/furnished

pages* _____ received by this Authority on _____

pages* _____ received by this Authority on _____

☐ the claims:

pages _____ as originally filed/furnished

pages* _____ as amended (together with any statement) under Article 19

pages* _____ received by this Authority on _____

pages* _____ received by this Authority on _____

☐ the drawings:

pages _____ as originally filed/furnished

pages* _____ received by this Authority on _____

pages* _____ received by this Authority on _____

☐ a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages _____

☐ the claims, Nos. _____

☐ the drawings, sheets/figs _____

☐ the sequence listing (specify): _____

☐ any table(s) related to the sequence listing (specify): _____

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

☐ the description, pages _____

☐ the claims, Nos. _____

☐ the drawings, sheets/figs _____

☐ the sequence listing (specify): _____

☐ any table(s) related to the sequence listing (specify): _____

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/SE2003/001216

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application☒ claims Nos. 9-10

because:

☒ the said international application, or the said claims Nos. 9-10
relate to the following subject matter which does not require an international preliminary examination (*specify*):

See PCT Rule 67.1.(iv).: Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _____
are so unclear that no meaningful opinion could be formed (*specify*):☐ the claims, or said claims Nos. _____ are so inadequately supported
by the description that no meaningful opinion could be formed.☐ no international search report has been established for said claims Nos. _____☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the
Administrative Instructions in that:

the written form

☐

has not been furnished

☐

does not comply with the standard

the computer readable form

☐

has not been furnished

☐

does not comply with the standard

☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with
the technical requirements provided for in the Annex C-bis of the Administrative Instructions.☐ See Supplemental Box for further details.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/SE2003/001216

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

| | | | |
|-------------------------------|--------|-------------------|-----|
| Novelty (N) | Claims | <u>1-8, 11-14</u> | YES |
| | Claims | | NO |
| Inventive step (IS) | Claims | | YES |
| | Claims | <u>1-8, 11-14</u> | NO |
| Industrial applicability (IA) | Claims | <u>1-8, 11-14</u> | YES |
| | Claims | | NO |

2. Citations and explanations (Rule 70.7)

Cited document:

D1) EP 1170594 A2

The present invention relates to novel 3-sulfonyl-indol-1-acetic acid derivatives for treatment of diseases mediated by PGD2 such as asthma or rhinitis.

Document D1 disclose structurally very closely related compounds (see compound 10c, page 34 and example 9) with the same activity as the claimed compounds.

The difference between the claimed compounds and the compounds in document is that compound 10c of D1 is that there is a sulfonyl-group in position 3 and that the aromatic group R3 is not condensed.

The problem to be solved by the present invention in the light of document A is the provision of alternative derivates of 3-substituted indol-1-acetic acids for treatment of diseases mediated by PGD2.

The applicant has not shown that the structural differences render the claimed compounds' unexpected effects in comparison with the known compounds'.

It is considered obvious to a person skilled in the art to modify structurally similar compounds to obtain the claimed compounds and come to the conclusion that they will have the same activity.

Thus, claims 1-8 and 11-14 are considered to fulfil the Requirement of novelty, but not that of inventive step.